Search

Your search keyword '"Zagozdzon A"' showing total 60 results
Start Over Author "Zagozdzon A" Publisher elsevier bv
60 results on '"Zagozdzon A"'

1. Safety and efficacy of cinacalcet in children below 3 years of age on maintenance dialysis

Author

Bernardor, Julie, primary, Flammier, Sacha, additional, Zagozdzon, Ilona, additional, Lalayiannis, Alexander D., additional, Koster-Kamphuis, Linda, additional, Verrina, Enrico, additional, Dorresteijn, Eiske, additional, Guzzo, Isabella, additional, Haffner, Dieter, additional, Shroff, Rukshana, additional, Schmitt, Claus P., additional, and Bacchetta, Justine, additional

Published
2024
Full Text
View/download PDF

2. Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction—Outcomes at two years

Author

Omerovic, Elmir, primary, James, Stefan, additional, Råmundal, Truls, additional, Fröbert, Ole, additional, Linder, Rikard, additional, Danielewicz, Mikael, additional, Hamid, Mehmet, additional, Pagonis, Christos, additional, Henareh, Loghman, additional, Wagner, Henrik, additional, Stewart, Jason, additional, Jensen, Jens, additional, Lindros, Pontus, additional, Robertsson, Lotta, additional, Wikström, Helena, additional, Ulvenstam, Anders, additional, Bhiladval, Pallonji, additional, Tödt, Tim, additional, Ioanes, Dan, additional, Kellerth, Thomas, additional, Zagozdzon, Leszek, additional, Götberg, Matthias, additional, Andersson, Jonas, additional, Angerås, Oskar, additional, Östlund, Ollie, additional, Held, Claes, additional, Koul, Sasha, additional, and Erlinge, David, additional

Published
2024
Full Text
View/download PDF

4. Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis

Author

Sklepkiewicz, Piotr, primary, Dymek, Barbara A., additional, Mlacki, Michal, additional, Koralewski, Robert, additional, Mazur, Marzena, additional, Nejman-Gryz, Patrycja, additional, Korur, Serdar, additional, Zagozdzon, Agnieszka, additional, Rymaszewska, Aleksandra, additional, von der Thüsen, Jan H., additional, Siwińska, Anna M., additional, Güner, Nazan Cemre, additional, Cheda, Łukasz, additional, Paplinska-Goryca, Magdalena, additional, Proboszcz, Małgorzata, additional, van den Bosch, Thierry P.P., additional, Górska, Katarzyna, additional, Golab, Jakub, additional, Kamiński, Rafał M., additional, Krenke, Rafał, additional, Golebiowski, Adam, additional, Dzwonek, Karolina, additional, and Dobrzanski, Pawel, additional

Published
2022
Full Text
View/download PDF

5. Refining genotype–phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants

Author

Burgmaier, Kathrin, primary, Brinker, Leonie, additional, Erger, Florian, additional, Beck, Bodo B., additional, Benz, Marcus R., additional, Bergmann, Carsten, additional, Boyer, Olivia, additional, Collard, Laure, additional, Dafinger, Claudia, additional, Fila, Marc, additional, Kowalewska, Claudia, additional, Lange-Sperandio, Bärbel, additional, Massella, Laura, additional, Mastrangelo, Antonio, additional, Mekahli, Djalila, additional, Miklaszewska, Monika, additional, Ortiz-Bruechle, Nadina, additional, Patzer, Ludwig, additional, Prikhodina, Larisa, additional, Ranchin, Bruno, additional, Ranguelov, Nadejda, additional, Schild, Raphael, additional, Seeman, Tomas, additional, Sever, Lale, additional, Sikora, Przemyslaw, additional, Szczepanska, Maria, additional, Teixeira, Ana, additional, Thumfart, Julia, additional, Uetz, Barbara, additional, Weber, Lutz Thorsten, additional, Wühl, Elke, additional, Zerres, Klaus, additional, Dötsch, Jörg, additional, Schaefer, Franz, additional, Liebau, Max Christoph, additional, Eid, Loai Akram, additional, Arbeiter, Klaus, additional, Godefroid, Nathalie, additional, Lombet, Jacques, additional, De Mul, Aurélie, additional, Feldkoetter, Markus, additional, Zieg, Jakub, additional, Grundmann, Franziska, additional, Galiano, Matthias, additional, Buchholz, Björn, additional, Buescher, Anja, additional, Häffner, Karsten, additional, Gross, Oliver, additional, Oh, Jun, additional, Haffner, Dieter, additional, Bernhardt, Wanja, additional, Schaefer, Susanne, additional, Wygoda, Simone, additional, Halbritter, Jan, additional, Derichs, Ute, additional, Klaus, Günter, additional, Lechner, Felix, additional, Ponsel, Sabine, additional, König, Jens, additional, Staude, Hagen, additional, Wurm, Donald, additional, Bald, Martin, additional, Gessner, Michaela, additional, Soliman, Neveen A., additional, Ariceta, Gema, additional, Gonzalez Rodriguez, Juan David, additional, Ojeda, Francisco de la Cerda, additional, Harambat, Jerome, additional, Morin, Denis, additional, Dossier, Claire, additional, Dorval, Guillaume, additional, Shroff, Rukshana, additional, Stabouli, Stella, additional, Hooman, Nakysa, additional, Mencarelli, Francesca, additional, Morello, William, additional, Longo, Germana, additional, Emma, Francesco, additional, Jankauskiene, Augustina, additional, Taranta-Janusz, Katarzyna, additional, Zagozdzon, Ilona, additional, Zachwieja, Katarzyna, additional, Stanczyk, Malgorzata, additional, Bienias, Beata, additional, Litwin, Mieczyslaw, additional, Morawiec-Knysak, Aurelia, additional, Afonso, Alberto Caldas, additional, Dunand, Oliver, additional, Rachisan, Andreea, additional, Miloševski-Lomić, Gordana, additional, Papizh, Svetlana, additional, Rus, Rina, additional, Jilani, Houweyda, additional, Atmis, Bahriye, additional, Duzova, Ali, additional, Soylu, Alper, additional, Candan, Cengiz, additional, Caliskan, Salim, additional, Yilmaz, Alev, additional, Gökce, İbrahim, additional, Akinci, Nurver, additional, Mir, Sevgi, additional, Dursun, Ismail, additional, Tabel, Yilmaz, additional, and Nalcacioglu, Hulya, additional

Published
2021
Full Text
View/download PDF

6. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study

Author

Erlinge, David, primary, Maehara, Akiko, additional, Ben-Yehuda, Ori, additional, Bøtker, Hans Erik, additional, Maeng, Michael, additional, Kjøller-Hansen, Lars, additional, Engstrøm, Thomas, additional, Matsumura, Mitsuaki, additional, Crowley, Aaron, additional, Dressler, Ovidiu, additional, Mintz, Gary S, additional, Fröbert, Ole, additional, Persson, Jonas, additional, Wiseth, Rune, additional, Larsen, Alf Inge, additional, Okkels Jensen, Lisette, additional, Nordrehaug, Jan Erik, additional, Bleie, Øyvind, additional, Omerovic, Elmir, additional, Held, Claes, additional, James, Stefan K, additional, Ali, Ziad A, additional, Muller, James E, additional, Stone, Gregg W, additional, Ahlehoff, Ole, additional, Amin, Azad, additional, Angerås, Oskar, additional, Appikonda, Praveen, additional, Balachandran, Saranya, additional, Barvik, Ståle, additional, Bendix, Kristoffer, additional, Bertilsson, Maria, additional, Boden, Ulrika, additional, Bogale, Nigussie, additional, Bonarjee, Vernon, additional, Calais, Fredrik, additional, Carlsson, Jörg, additional, Carstensen, Steen, additional, Christersson, Christina, additional, Christiansen, Evald Høj, additional, Corral, Maria, additional, De Backer, Ole, additional, Dhaha, Usama, additional, Dworeck, Christian, additional, Eggers, Kai, additional, Elfström, Charlotta, additional, Ellert, Julia, additional, Eriksen, Erlend, additional, Fallesen, Christian, additional, Forsman, Margareta, additional, Fransson, Helena, additional, Gaballa, Mohsen, additional, Gacki, Marek, additional, Götberg, Matthias, additional, Hagström, Lars, additional, Hallberg, Theresa, additional, Hambraeus, Kristina, additional, Haraldsson, Inger, additional, Harnek, Jan, additional, Havndrup, Ole, additional, Hegbom, Knut, additional, Heigert, Matthias, additional, Helqvist, Steffen, additional, Herstad, Jon, additional, Hijazi, Ziad, additional, Holmvang, Lene, additional, Ioanes, Dan, additional, Iqbal, Amjid, additional, Iversen, Allan, additional, Jacobson, Jaclyn, additional, Jakobsen, Lars, additional, Jankovic, Ivana, additional, Jensen, Ulf, additional, Jensevik, Karin, additional, Johnston, Nina, additional, Jonasson, Torfi Fjalar, additional, Jørgensen, Erik, additional, Joshi, Francis, additional, Kajermo, Ulf, additional, Kåver, Frida, additional, Kelbæk, Henning, additional, Kellerth, Thomas, additional, Kish, Mitra, additional, Koenig, Wolfgang, additional, Koul, Sasha, additional, Lagerqvist, Bo, additional, Larsson, Bertil, additional, Lassen, Jens Flensted, additional, Leiren, Olav, additional, Li, Zhe, additional, Lidell, Christer, additional, Linder, Rikard, additional, Lindstaedt, Michael, additional, Lindström, Gunilla, additional, Liu, Shen, additional, Løland, Kjetil Halvorsen, additional, Lønborg, Jacob, additional, Márton, László, additional, Mir-Akbari, Habib, additional, Mohamed, Shameema, additional, Odenstedt, Jacob, additional, Ogne, Christer, additional, Oldgren, Jonas, additional, Olivecrona, Göran, additional, Östlund-Papadogeorgos, Nikolas, additional, Ottesen, Michael, additional, Packer, Erik, additional, Palmquist, Åsa Michelgård, additional, Paracha, Quratulain, additional, Pedersen, Frans, additional, Petursson, Petur, additional, Råmunddal, Truls, additional, Rotevatn, Svein, additional, Sanchez, Raquel, additional, Sarno, Giovanna, additional, Saunamäki, Kari I, additional, Scherstén, Fredrik, additional, Serruys, Patrick W, additional, Sjögren, Iwar, additional, Sørensen, Rikke, additional, Srdanovic, Iva, additional, Subhani, Zuka, additional, Svensson, Eva, additional, Thuesen, Anne, additional, Tijssen, Jan, additional, Tilsted, Hans-Henrik, additional, Tödt, Tim, additional, Trovik, Thor, additional, Våga, Bjørn Inge, additional, Varenhorst, Christoph, additional, Veien, Karsten, additional, Vestman, Emma, additional, Völz, Sebastian, additional, Wallentin, Lars, additional, Wykrzykowska, Joanna, additional, Zagozdzon, Leszek, additional, Zamfir, Manuela, additional, Zedigh, Crister, additional, Zhong, Hang, additional, and Zhou, Zhipeng, additional

Published
2021
Full Text
View/download PDF

7. Novel Silicon Titanium Diboride Micropatterned Substrates for Cellular Patterning

Author

W. Zagozdzon-Wosik, Jefferson Friguglietti, Omaima M. Sabek, Phi Le, Daniel W. Fraga, Jianhua Gu, Lewis Francis, Darius McPhail, Fatima A. Merchant, A. Osama Gaber, Marcos Quintela, Salvatore A. Gazze, and Susmi Das

Subjects
Boron Compounds, Silicon, Materials science, Biophysics, Bioengineering, Nanotechnology, 02 engineering and technology, Soft lithography, law.invention, Biomaterials, 03 medical and health sciences, chemistry.chemical_compound, law, Cell Adhesion, Humans, Surface charge, 030304 developmental biology, Titanium, 0303 health sciences, Durotaxis, Cell growth, Mesenchymal Stem Cells, 021001 nanoscience & nanotechnology, chemistry, Mechanics of Materials, Cell culture, Ceramics and Composites, Surface modification, Photolithography, 0210 nano-technology, Titanium diboride
Abstract

Both hard material photolithography and soft lithography are widely used for patterned cell culture. Soft lithography techniques enable bioactive molecule incorporation, however complex surface modifications are required to introduce specific ligands or proteins in conventional photolithography. In this study, we demonstrate human umbilical vein cell (HUVEC) and adult bone marrow derived mesenchymal stem cell (MSC) patterning on titanium diboride (TiB2) layers deposited on silicon (Si) substrates by electron-beam evaporation and micropatterned using photolithography. Micropatterned cell growth specificity on geometric shapes of circle and/or lines is achieved via differential growth factors adsorption in the presence of heparin. Specifically, the deposited films of TiB2 showed increased stiffness, hardness, hydrophilicity and surface charge when compared to background Si. These substrates were found to be compatible with HUVEC and MSC viability, based on biomarker expression and RNA-sequence transcriptome analysis. Cell-type dependent, micropattern selective cell growth, such as contact guidance, alignment, and durotaxis, were observed. In addition, MSC clustering was achieved, enabling a three-dimensional (3D) aggregate based microenvironment during culture. This study clearly demonstrates the potential of microfabricated Si and TiB2 biomaterials for patterned cell culture in vitro, independent of any additional surface modification.

Published
2020

8. Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase

Author

Robert Koralewski, Gleb Andryianau, Krzysztof Matyszewski, Bartlomiej Borek, Pluta Elzbieta, Adam Golebiowski, Marcin Mazurkiewicz, Jakub Golab, Barbara Dymek, Piotr Niedziejko, Czestkowski Wojciech J, Michal Piotrowicz, Michał Kowalski, Sylwia Olejniczak, Marzena Mazur, Jacek Olczak, Agnieszka Zagozdzon, Filip Stefaniak, Karolina Dzwonek, Agnieszka Bartoszewicz, Mariusz Gruza, and Magdalena Salamon

Subjects
0301 basic medicine, Clinical Biochemistry, Administration, Oral, Biological Availability, Pharmaceutical Science, Biochemistry, Enzymatic Assays, Small Molecule Libraries, Mice, Structure-Activity Relationship, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pharmacokinetics, Drug Discovery, Animals, High activity, 030212 general & internal medicine, Molecular Biology, Dose-Response Relationship, Drug, Molecular Structure, Organic Chemistry, Small molecule, 3. Good health, Bioavailability, Molecular Docking Simulation, Hexosaminidases, 030104 developmental biology, chemistry, Molecular Medicine, Selectivity, Lead compound
Abstract

This article describes our work towards the identification of a potent and selective inhibitor of mouse chitotriosidase (mCHIT1). A series of small molecule inhibitors of mCHIT1 and mAMCase have been developed from early lead compound 1 . Examination of synthetized analogues led to discovery of several novel highly potent compounds. Among them compound 9 ( OAT-2068 ) displays a remarkable 143-fold mCHIT1 vs . mAMCase selectivity. To explain the observed SAR molecular docking experiments were performed, which were in line with the experimental data from the enzymatic assays. Inhibitor 9 ( OAT-2068 ) was found to have an excellent pharmacokinetic profile. This, together with high activity and selectivity, makes the compound an ideal and unique tool for studying the role of CHIT1 in biological models.

Published
2018

10. Novel Silicon Titanium Diboride Micropatterned Substrates for Cellular Patterning

Author

Friguglietti, Jefferson, primary, Das, Susmi, additional, Le, Phi, additional, Fraga, Daniel, additional, Quintela, Marcos, additional, Gazze, Salvatore A., additional, McPhail, Darius, additional, Gu, Jianhua, additional, Sabek, Omaima, additional, Gaber, A. Osama, additional, Francis, Lewis W., additional, Zagozdzon-Wosik, Wanda, additional, and Merchant, Fatima A., additional

Published
2020
Full Text
View/download PDF

12. Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe: an ESPN-ERA/EDTA registry analysis

Author

Laura Espinosa, Elisabeth A.M. Cornelissen, Sylvie Cloarec, Ilona Zagozdzon, Sergey Baiko, Anna Bjerre, Marjolein Bonthuis, Diamant Shtiza, Nicholas C. Chesnaye, Rosário Stone, Kitty J. Jager, Rebecca Holman, Jérôme Harambat, Franz Schaefer, James G. Heaf, Jaap W. Groothoff, Esra Baskin, Karlijn J. van Stralen, Medical Informatics, ARD - Amsterdam Reproduction and Development, Other departments, APH - Aging & Later Life, APH - Quality of Care, Paediatric Nephrology, APH - Methodology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, APH - Global Health, APH - Health Behaviors & Chronic Diseases, and ACS - Pulmonary hypertension & thrombosis

Subjects
Male, Pediatrics, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Population, 030232 urology & nephrology, Health Services Accessibility, End stage renal disease, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Humans, Medicine, Registries, 030212 general & internal medicine, Renal replacement therapy, Healthcare Disparities, Child, education, Proportional Hazards Models, education.field_of_study, business.industry, Mortality rate, Hazard ratio, Infant, Newborn, Infant, General Medicine, Explained variation, Health equity, Europe, Renal Replacement Therapy, Child mortality, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Child, Preschool, Kidney Failure, Chronic, Female, business
Abstract

Item does not contain fulltext BACKGROUND: We explored the variation in country mortality rates in the paediatric population receiving renal replacement therapy across Europe, and estimated how much of this variation could be explained by patient-level and country-level factors. METHODS: In this registry analysis, we extracted patient data from the European Society for Paediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry for 32 European countries. We included incident patients younger than 19 years receiving renal replacement therapy. Adjusted hazard ratios (aHR) and the explained variation were modelled for patient-level and country-level factors with multilevel Cox regression. The primary outcome studied was all-cause mortality while on renal replacement therapy. FINDINGS: Between Jan 1, 2000, and Dec 31, 2013, the overall 5 year renal replacement therapy mortality rate was 15.8 deaths per 1000 patient-years (IQR 6.4-16.4). France had a mortality rate (9.2) of more than 3 SDs better, and Russia (35.2), Poland (39.9), Romania (47.4), and Bulgaria (68.6) had mortality rates more than 3 SDs worse than the European average. Public health expenditure was inversely associated with mortality risk (per SD increase, aHR 0.69, 95% CI 0.52-0.91) and explained 67% of the variation in renal replacement therapy mortality rates between countries. Child mortality rates showed a significant association with renal replacement therapy mortality, albeit mediated by macroeconomics (eg, neonatal mortality reduced from 1.31 [95% CI 1.13-1.53], p=0.0005, to 1.21 [0.97-1.51], p=0.10). After accounting for country distributions of patient age, the variation in renal replacement therapy mortality rates between countries increased by 21%. INTERPRETATION: Substantial international variation exists in paediatric renal replacement therapy mortality rates across Europe, most of which was explained by disparities in public health expenditure, which seems to limit the availability and quality of paediatric renal care. Differences between countries in their ability to accept and treat the youngest patients, who are the most complex and costly to treat, form an important source of disparity within this population. Our findings can be used by policy makers and health-care providers to explore potential strategies to help reduce these health disparities. FUNDING: ERA-EDTA and ESPN.

Published
2017

13. Mortality risk in European children with end-stage renal disease on dialysis

Author

Franz Schaefer, Ilona Zagozdzon, Jaap W. Groothoff, Dusan Paripovic, James G. Heaf, Nicholas C. Chesnaye, Kitty J. Jager, György Reusz, Malcolm Lewis, Karlijn J. van Stralen, Elisabeth Maurer, Marjolein Bonthuis, APH - Amsterdam Public Health, Medical Informatics, Graduate School, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Paediatric Nephrology, ACS - Amsterdam Cardiovascular Sciences, and Other departments

Subjects
Male, Pediatrics, medicine.medical_specialty, Time Factors, Adolescent, medicine.medical_treatment, Population, 030232 urology & nephrology, 030204 cardiovascular system & hematology, Infections, End stage renal disease, Peritoneal dialysis, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Renal Dialysis, Risk Factors, medicine, Humans, Registries, Child, Propensity Score, education, Survival rate, Dialysis, Proportional Hazards Models, education.field_of_study, business.industry, Mortality rate, Hazard ratio, Age Factors, Infant, Newborn, Infant, 3. Good health, Europe, Survival Rate, Cardiovascular Diseases, Nephrology, Child, Preschool, Kidney Failure, Chronic, Female, Hemodialysis, business, Peritoneal Dialysis
Abstract

We aimed to describe survival in European pediatric dialysis patients and compare the differential mortality risk between patients starting on hemodialysis (HD) and peritoneal dialysis (PD). Data for 6473 patients under 19 years of age or younger were extracted from the European Society of Pediatric Nephrology, the European Renal Association, and European Dialysis and Transplant Association Registry for 36 countries for the years 2000 through 2013. Hazard ratios (HRs) were adjusted for age at start of dialysis, sex, primary renal disease, and country. A secondary analysis was performed on a propensity score-matched (PSM) cohort. The overall 5-year survival rate in European children starting on dialysis was 89.5% (95% confidence interval [CI] 87.7%-91.0%). The mortality rate was 28.0 deaths per 1000 patient years overall. This was highest (36.0/1000) during the first year of dialysis and in the 0- to 5-year age group (49.4/1000). Cardiovascular events (18.3%) and infections (17.0%) were the main causes of death. Children selected to start on HD had an increased mortality risk compared with those on PD (adjusted HR 1.39, 95% CI 1.06-1.82, PSM HR 1.46, 95% CI 1.06-2.00), especially during the first year of dialysis (HD/PD adjusted HR 1.70, 95% CI 1.22-2.38, PSM HR 1.79, 95% CI 1.20-2.66), when starting at older than 5 years of age (HD/PD: adjusted HR 1.58, 95% CI 1.03-2.43, PSM HR 1.87, 95% CI 1.17-2.98) and when children have been seen by a nephrologist for only a short time before starting dialysis (HD/PD adjusted HR 6.55, 95% CI 2.35-18.28, PSM HR 2.93, 95% CI 1.04-8.23). Because unmeasured case-mix differences and selection bias may explain the higher mortality risk in the HD population, these results should be interpreted with caution.

Published
2016

15. Selenium-containing polysaccharides from Lentinula edodes—Biological activity

Author

Sandra Górska, Marcin Cieślak, Beata Kaleta, Radoslaw Zagozdzon, Julia Kaźmierczak-Barańska, Jadwiga Turło, Andrzej Górski, Eliza Malinowska, Marzenna Klimaszewska, and Barbara Nawrot

Subjects
Polymers and Plastics, Cell Survival, T-Lymphocytes, Lentinan, Shiitake Mushrooms, chemistry.chemical_element, Antineoplastic Agents, Polysaccharide, medicine.disease_cause, Peripheral blood mononuclear cell, Selenium, Structure-Activity Relationship, chemistry.chemical_compound, Polysaccharides, Human Umbilical Vein Endothelial Cells, Materials Chemistry, medicine, Humans, Viability assay, Cell Proliferation, chemistry.chemical_classification, Dose-Response Relationship, Drug, Organic Chemistry, Biological activity, In vitro, Oxidative Stress, Biochemistry, chemistry, Drug Screening Assays, Antitumor, Reactive Oxygen Species, Immunosuppressive Agents, Oxidative stress, Granulocytes, HeLa Cells
Abstract

We hypothesized that selenium(Se)-enriched polysaccharides would possess superior biological activity when compared to those non-enriched. To verify this hypothesis, we obtained by biotechnological methods a Se-enriched analog of Japanese anticancer drug lentinan and, as a reference, the non-Se-enriched fraction. We tested the effects of the obtained fractions on the proliferation of human peripheral blood mononuclear cells. The results suggested a selective immunosuppressive activity, non-typical for mushroom derived polysaccharides. Both fractions caused significant inhibition of human T lymphocyte proliferation induced by mitogens, without significant effects on B lymphocytes. The inhibitory effect was not due to the toxicity of the examined polysaccharides. In normal (HUVEC) or malignant (HeLa) cells tested fractions significantly enhanced cell viability and protected the cells from oxidative stress conditions. However, we observed no effect of the polysaccharide fractions on the production of reactive oxygen species by granulocytes in vitro. The selenium content increased the biological activity of the tested polysaccharide fractions.

Published
2019

16. Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate

Author

Graczyk-Jarzynka, Agnieszka, primary, Goral, Agnieszka, additional, Muchowicz, Angelika, additional, Zagozdzon, Radoslaw, additional, Winiarska, Magdalena, additional, Bajor, Malgorzata, additional, Trzeciecka, Anna, additional, Fidyt, Klaudyna, additional, Krupka, Joanna Alicja, additional, Cyran, Julia, additional, Szczygiel, Kacper, additional, Efremov, Dimitar G., additional, Gobessi, Stefania, additional, Jagielski, Adam, additional, Siudakowska, Karolina, additional, Bobrowicz, Malgorzata, additional, Klopotowska, Marta, additional, Barankiewicz, Joanna, additional, Malenda, Agata, additional, Lech-Maranda, Ewa, additional, Miazek-Zapala, Nina, additional, Skarzynski, Piotr Henryk, additional, Domagala, Antoni, additional, Golab, Jakub, additional, and Firczuk, Malgorzata, additional

Published
2019
Full Text
View/download PDF

17. Adenanthin targets proteins involved in the regulation of disulphide bonds

Author

Jakub Golab, Malgorzata Firczuk, Joanna Barankiewicz, Jian-Xin Pu, Angelika Muchowicz, Ryszard Ostaszewski, Han-Dong Sun, Anna Trzeciecka, Joanna Stachura, Justyna Chlebowska, Dominika Nowis, Szymon Klossowski, and Radoslaw Zagozdzon

Subjects
Pharmacology, Plant Extracts, Chemistry, Binding protein, Plant Components, Aerial, Reductase, Thioredoxin fold, Biochemistry, 3. Good health, Protein Transport, HEK293 Cells, Thioredoxins, Cell Line, Tumor, Biotinylation, Isodon, Humans, Disulfides, Diterpenes, Thioredoxin, Peroxiredoxin, Structural motif, Protein disulfide-isomerase
Abstract

Adenanthin has been recently shown to inhibit the enzymatic activities of peroxiredoxins (Prdx) land II through its functional alpha,beta-unsaturated ketone group serving as a Michael acceptor. A similar group is found in SK053, a compound recently developed by our group to target the thioredoxin-thioredoxin reductase (Trx-TrxR) system. This work provides evidence that next to Prdx I and II adenanthin targets additional proteins including thioredoxin-thioredoxin reductase system as well as protein disulfide isomerase (PDI) that contain a characteristic structural motif, referred to as a thioredoxin fold. Adenanthin inhibits the activity of Trx-TR system and PDI in vitro in the insulin reduction assay and decreases the activity of Trx in cultured cells. Moreover, we identified Trx-1 as an adenanthin binding protein in cells incubated with biotinylated adenanthin as an affinity probe. The results of our studies indicate that adenanthin is a mechanism-selective, rather than an enzyme-specific inhibitor of enzymes containing readily accessible, nucleophilic cysteines. This observation might be of importance in considering potential therapeutic applications of adenanthin to include a range of diseases, where aberrant activity of Prdx, Trx-TrxR and PDI is involved in their pathogenesis. (C) 2014 Elsevier Inc. All rights reserved.

Published
2014

18. Risk Factors for Early Dialysis Dependency in Autosomal Recessive Polycystic Kidney Disease

Author

Burgmaier, Kathrin, primary, Kunzmann, Kevin, additional, Ariceta, Gema, additional, Bergmann, Carsten, additional, Buescher, Anja Katrin, additional, Burgmaier, Mathias, additional, Dursun, Ismail, additional, Duzova, Ali, additional, Eid, Loai, additional, Erger, Florian, additional, Feldkoetter, Markus, additional, Galiano, Matthias, additional, Geßner, Michaela, additional, Goebel, Heike, additional, Gokce, Ibrahim, additional, Haffner, Dieter, additional, Hooman, Nakysa, additional, Hoppe, Bernd, additional, Jankauskiene, Augustina, additional, Klaus, Guenter, additional, König, Jens, additional, Litwin, Mieczyslaw, additional, Massella, Laura, additional, Mekahli, Djalila, additional, Melek, Engin, additional, Mir, Sevgi, additional, Pape, Lars, additional, Prikhodina, Larisa, additional, Ranchin, Bruno, additional, Schild, Raphael, additional, Seeman, Tomas, additional, Sever, Lale, additional, Shroff, Rukshana, additional, Soliman, Neveen A., additional, Stabouli, Stella, additional, Stanczyk, Malgorzata, additional, Tabel, Yilmaz, additional, Taranta-Janusz, Katarzyna, additional, Testa, Sara, additional, Thumfart, Julia, additional, Topaloglu, Rezan, additional, Weber, Lutz Thorsten, additional, Wicher, Dorota, additional, Wühl, Elke, additional, Wygoda, Simone, additional, Yilmaz, Alev, additional, Zachwieja, Katarzyna, additional, Zagozdzon, Ilona, additional, Zerres, Klaus, additional, Dötsch, Jörg, additional, Schaefer, Franz, additional, Liebau, Max Christoph, additional, Ranguelov, Nadejda, additional, Godefroid, Nathalie, additional, Collard, Laure, additional, Lombet, Jacques, additional, Maquet, Julie, additional, Schalk, Gesa, additional, Querfeld, Uwe, additional, Beck, Bodo B., additional, Benzing, Thomas, additional, Buettner, Reinhard, additional, Grundmann, Franziska, additional, Kurschat, Christine, additional, Benz, Kerstin, additional, Tzschoppe, Anja, additional, Buchholz, Björn, additional, Buescher, Rainer, additional, Häffner, Karsten, additional, Pohl, Martin, additional, Gross, Oliver, additional, Krügel, Jenny, additional, Stock, Johanna, additional, Patzer, Ludwig, additional, Oh, Jun, additional, Bernhardt, Wanja, additional, Doyon, Anke, additional, Vinke, Tobias, additional, Sander, Anja, additional, Henn, Michael, additional, Derichs, Ute, additional, Beetz, Rolf, additional, Jeck, Nikola, additional, Lange-Sperandio, Bärbel, additional, Ponsel, Sabine, additional, Kusser, Franziska, additional, Uetz, Barbara, additional, Benz, Marcus, additional, Schmidt, Silke, additional, Huppertz-Kessler, Christina, additional, Kranz, Birgitta, additional, Titieni, Andrea, additional, Wurm, Donald, additional, Leichter, Heinz E., additional, Bald, Martin, additional, Billing, Heiko, additional, Nabhan, Marwa M., additional, Lara, Luis Enrique, additional, Papachristou, Fotios, additional, Emma, Francesco, additional, Cerkauskiene, Rimante, additional, Azukaitis, Karolis, additional, Wasilewska, Anna, additional, Balasz-Chmielewska, Irena, additional, Miklaszewska, Monika, additional, Tkaczyk, Marcin, additional, Sikora, Przemyslaw, additional, Zaniew, Marcin, additional, Niemirska, Ania, additional, Antoniewicz, Jolanta, additional, Lesiak, Justyna, additional, Afonso, Alberto Caldas, additional, Teixeira, Ana, additional, Milosevski-Lomic, Gordana, additional, Paripović, Dusan, additional, Peco-Antic, Amira, additional, Papizh, Svetlana, additional, Bayazit, Aysun Karabay, additional, Anarat, Ali, additional, Soylu, Alper, additional, Kavukcu, Salih, additional, Candan, Cengiz, additional, Caliskan, Salim, additional, Canpolat, Nur, additional, Emre, Sevinc, additional, Alpay, Harika, additional, Akinci, Nurver, additional, Conkar, Secil, additional, Poyrazoglu, Hakan M., additional, and Dusunsel, Ruhan, additional

Published
2018
Full Text
View/download PDF

20. Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase

Author

Mazur, Marzena, primary, Bartoszewicz, Agnieszka, additional, Dymek, Barbara, additional, Salamon, Magdalena, additional, Andryianau, Gleb, additional, Kowalski, Michał, additional, Olejniczak, Sylwia, additional, Matyszewski, Krzysztof, additional, Pluta, Elżbieta, additional, Borek, Bartłomiej, additional, Stefaniak, Filip, additional, Zagozdzon, Agnieszka, additional, Mazurkiewicz, Marcin, additional, Koralewski, Robert, additional, Czestkowski, Wojciech, additional, Piotrowicz, Michał, additional, Niedziejko, Piotr, additional, Gruza, Mariusz M., additional, Dzwonek, Karolina, additional, Golebiowski, Adam, additional, Golab, Jakub, additional, and Olczak, Jacek, additional

Published
2018
Full Text
View/download PDF

21. The No-Touch Saphenous Vein as the Preferred Second Conduit for Coronary Artery Bypass Grafting

Author

John D. Mannion, Lennart Bodin, Hans Olsson, Leszek Zagozdzon, Mats Dreifaldt, and Domingos S. R. Souza

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Time Factors, Bypass grafting, Coronary Artery Disease, Coronary Angiography, Coronary artery disease, medicine.artery, medicine, Humans, Vascular Patency, Saphenous Vein, Coronary Artery Bypass, Mammary Arteries, Radial artery, Vein, Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, Ultrasonography, Doppler, Middle Aged, medicine.disease, Surgery, Coronary arteries, Treatment Outcome, surgical procedures, operative, medicine.anatomical_structure, Radial Artery, Angiography, Female, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies, Artery
Abstract

Background Injury incurred while saphenous veins are being obtained results in poor graft patency and impairs the results of coronary artery bypass grafting. A novel method of obtaining veins, the no-touch technique, has shown improved long-term saphenous vein graft patency. Methods This randomized trial included 108 patients undergoing coronary artery bypass grafting and compared the patency of no-touch saphenous vein with that of radial artery grafts. Each patient was assigned to receive one no-touch saphenous vein and one radial artery graft to either the left or the right coronary territory to complement the left internal thoracic artery. Results Angiography was performed in 99 patients (92%) at a mean of 36 months postoperatively. Graft and grafted coronary artery patency was evaluated. The patency of grafts for no-touch saphenous vein and radial artery was 94% versus 82% ( p = 0.01), respectively. The patency of coronary arteries grafted with no-touch saphenous vein and radial artery grafts was 95% versus 84% ( p = 0.005), respectively. Eighty-nine of 96 (93%) left internal thoracic artery grafts were patent. Conclusions No-touch saphenous vein grafts showed a significantly higher patency rate than the radial artery grafts and the patency was comparable to the patency for left internal thoracic artery grafts. This highlights the improvement in saphenous vein graft quality with the no-touch technique and increases the number of situations in which saphenous veins may be preferable to radial artery grafts as conduits in coronary artery bypass grafting.

Published
2013

22. Inverted Valve After Initially Successful Transfemoral Aortic Valve Implantation

Author

Lena Sunnermalm, Örjan Friberg, Leszek Zagozdzon, Tor Damén, Tomas Kellert, and Bo Cederstrand

Subjects
Pulmonary and Respiratory Medicine, Aortic valve, medicine.medical_specialty, medicine.medical_treatment, Autopsy, Femoral artery, Fatal Outcome, medicine.artery, Internal medicine, Humans, Medicine, Cardiopulmonary resuscitation, Intraoperative Complications, Aged, Heart Valve Prosthesis Implantation, business.industry, Extracorporeal circulation, Aortic Valve Stenosis, Pulmonary edema, medicine.disease, Prosthesis Failure, Surgery, Femoral Artery, Stenosis, medicine.anatomical_structure, Blood pressure, Aortic Valve, Heart Valve Prosthesis, cardiovascular system, Cardiology, Female, Cardiology and Cardiovascular Medicine, business
Abstract

A 73-year-old woman with severe aortic stenosis was accepted for transcatheter aortic valve implantation. There was minimal paravalvular leakage after the implantation, and the patient was stable. Twelve minutes after the implantation, the arterial pressure suddenly dropped. Transesophageal echocardiography showed severe left ventricular dysfunction. Cardiopulmonary resuscitation was started, and initially was successful with a systolic blood pressure of 90 mm Hg. However, despite initiation of extracorporeal circulation support, the patient deteriorated, pulmonary edema developed, and she died. Autopsy revealed an inverted aortic valve. The reasons why the patient had cardiac arrest and an inverted transfemoral aortic valve remain unclear.

Published
2012

23. Reduction of electrode polarization capacitance in low-frequency impedance spectroscopy by using mesh electrodes

Author

John H. Miller, W. Zagozdzon-Wosik, Jarek Wosik, and Divya Padmaraj

Subjects
Materials science, Biomedical Engineering, Biophysics, Analytical chemistry, Biosensing Techniques, Dielectric, Electric Capacitance, Capacitance, Mitochondria, Heart, Mice, Electric field, Electric Impedance, Electrochemistry, Electrode array, Animals, Computer Simulation, Electrodes, Heart metabolism, Membrane Potential, Mitochondrial, business.industry, Electric Conductivity, Charge density, General Medicine, Dielectric Spectroscopy, Electrode, Optoelectronics, business, Biotechnology
Abstract

Dielectric measurements of biological samples are obscured by electrode polarization, which at low frequencies dominates over the actual sample response. Reduction of this artifact is especially necessary in studying interactions of electric field with biological systems in the α-dispersion range. We developed a method to reduce the influence of electrode polarization by employing mesh instead of solid electrodes as sensing probes, thereby reducing the area of the double layer. The design decreases the electrode-electrolyte contact area by almost 40% while keeping the bulk sample capacitance the same. Interrogation electric fields away from the electrode surface and sensitivity are unaffected. Electrodes were microfabricated (600μm×50μm, spacing of 100μm) with and without mesh holes 7.5μm×7.5μm in size. Simulations of electric field performed using Comsol Multiphysics showed non-uniformity of the electric field within less than 1.5μm from the electrode surface, which encompasses the double layer region, but at greater distance the solid and mesh electrodes gave the same results. Mesh electrodes reduced capacitance measurements for water and KCl solutions of different concentrations at low frequencies (

Published
2011

24. Infants Requiring Maintenance Dialysis: Outcomes of Hemodialysis and Peritoneal Dialysis

Author

Vidal, Enrico, primary, van Stralen, Karlijn J., additional, Chesnaye, Nicholas C., additional, Bonthuis, Marjolein, additional, Holmberg, Christer, additional, Zurowska, Aleksandra, additional, Trivelli, Antonella, additional, Da Silva, José Eduardo Esteves, additional, Herthelius, Maria, additional, Adams, Brigitte, additional, Bjerre, Anna, additional, Jankauskiene, Augustina, additional, Miteva, Polina, additional, Emirova, Khadizha, additional, Bayazit, Aysun K., additional, Mache, Christoph J., additional, Sánchez-Moreno, Ana, additional, Harambat, Jérôme, additional, Groothoff, Jaap W., additional, Jager, Kitty J., additional, Schaefer, Franz, additional, Verrina, Enrico, additional, Shtiza, D., additional, Kramar, R., additional, Oberbauer, R., additional, Baiko, S., additional, Sukalo, A., additional, van Hoeck, K., additional, Collart, F., additional, des Grottes, J.M., additional, Pokrajac, D., additional, Roussinov, D., additional, Batinić, D., additional, Lemac, M., additional, Slavicek, J., additional, Seeman, T., additional, Vondrak, K., additional, Heaf, J.G., additional, Toots, U., additional, Finne, P., additional, Grönhagen-Riska, C., additional, Couchoud, C., additional, Lasalle, M., additional, Sahpazova, E., additional, Abazi, N., additional, Ristoka Bojkovska, N., additional, von Gersdorff, G., additional, Scholz, C., additional, Tönshoff, B., additional, Krupka, K., additional, Höcker, B., additional, Pape, L., additional, Afentakis, N., additional, Kapogiannis, A., additional, Printza, N., additional, Reusz, G., additional, Berecki, C.S., additional, Szabó, A., additional, Szabó, T., additional, Györke, Z.S., additional, Kis, E., additional, Palsson, R., additional, Edvardsson, V., additional, Gianoglio, B., additional, Maringhini, S., additional, Pecoraro, C., additional, Picca, S., additional, Testa, S., additional, Rudaitis, S., additional, Said-Conti, V., additional, Gatcan, S., additional, Berbeca, O., additional, Zaikova, N., additional, Pavićević, S., additional, Leivestad, T., additional, Zagozdzon, I., additional, Mota, C., additional, Almeida, M., additional, Afonso, C., additional, Mircescu, G., additional, Garneata, L., additional, Molchanova, E.A., additional, Tomilina, N.A., additional, Bikbov, B.T., additional, Kostic, M., additional, Peco-Antic, A., additional, Spasojevic-Dimitrijeva, B., additional, Milosevski-Lomic, G., additional, Paripovic, D., additional, Puric, S., additional, Kruscic, D., additional, Podracka, L., additional, Kolvek, G., additional, Buturovic-Ponikvar, J., additional, Novljan, G., additional, Battelino, N., additional, Alonso Melgar, A., additional, Schön, S., additional, Prütz, K.G., additional, Backmän, L., additional, Stendahl, M., additional, Evans, M., additional, Rippe, B., additional, Kuenhi, C.E., additional, Maurer, E., additional, Laube, G.F., additional, Tschumi, S., additional, Parvex, P., additional, Hoitsma, A., additional, Hemke, A., additional, Topaloglu, R., additional, Ivanov, D., additional, Pruthi, R., additional, Braddon, F., additional, Mannings, S., additional, Cassula, A., additional, and Sinha, M.D., additional

Published
2017
Full Text
View/download PDF

25. Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe: an ESPN-ERA/EDTA registry analysis

Author

Chesnaye, Nicholas C, primary, Schaefer, Franz, additional, Bonthuis, Marjolein, additional, Holman, Rebecca, additional, Baiko, Sergey, additional, Baskın, Esra, additional, Bjerre, Anna, additional, Cloarec, Sylvie, additional, Cornelissen, Elisabeth A M, additional, Espinosa, Laura, additional, Heaf, James, additional, Stone, Rosário, additional, Shtiza, Diamant, additional, Zagozdzon, Ilona, additional, Harambat, Jérôme, additional, Jager, Kitty J, additional, Groothoff, Jaap W, additional, and van Stralen, Karlijn J, additional

Published
2017
Full Text
View/download PDF

26. Kinase-Independent Function of Cyclin E

Author

James M. Roberts, Bruce E. Clurman, Yan Geng, Piotr Sicinski, Jherek Swanger, Joel D. Winer, Philipp Kaldis, Agnieszka Zagozdzon, Markus Welcker, and Young-Mi Lee

Subjects
Cyclin E, Cyclin D, Cyclin A, Cyclin B, Cell Cycle Proteins, Models, Biological, Resting Phase, Cell Cycle, S Phase, Mice, Cyclin-dependent kinase, Animals, Humans, Molecular Biology, Cyclin, biology, DNA Helicases, Oncogenes, Cell Biology, Chromatin, Cyclin-Dependent Kinases, Cell biology, DNA-Binding Proteins, Protein Transport, Phenotype, embryonic structures, biology.protein, Cyclin-dependent kinase complex, Mutant Proteins, Cyclin A2, HeLa Cells, Protein Binding
Abstract

E-type cyclins are thought to drive cell-cycle progression by activating cyclin-dependent kinases, primarily CDK2. We previously found that cyclin E-null cells failed to incorporate MCM helicase into DNA prereplication complex during G(0) --> S phase progression. We now report that a kinase-deficient cyclin E mutant can partially restore MCM loading and S phase entry in cyclin E-null cells. We found that cyclin E is loaded onto chromatin during G(0) --> S progression. In the absence of cyclin E, CDT1 is normally loaded onto chromatin, whereas MCM is not, indicating that cyclin E acts between CDT1 and MCM loading. We observed a physical association of cyclin E with CDT1 and with MCMs. We propose that cyclin E facilitates MCM loading in a kinase-independent fashion, through physical interaction with CDT1 and MCM. Our work indicates that-in addition to their function as CDK activators-E cyclins play kinase-independent functions in cell-cycle progression.

Published
2007
Full Text
View/download PDF

27. Kidney Versus Combined Kidney and Liver Transplantation in Young People With Autosomal Recessive Polycystic Kidney Disease: Data From the European Society for Pediatric Nephrology/European Renal Association−European Dialysis and Transplant (ESPN/ERA-EDTA) Registry

Author

Mekahli, Djalila, primary, van Stralen, Karlijn J., additional, Bonthuis, Marjolein, additional, Jager, Kitty J., additional, Balat, Ayşe, additional, Benetti, Elisa, additional, Godefroid, Nathalie, additional, Edvardsson, Vidar O., additional, Heaf, James G., additional, Jankauskiene, Augustina, additional, Kerecuk, Larissa, additional, Marinova, Svetlana, additional, Puteo, Flora, additional, Seeman, Tomas, additional, Zurowska, Aleksandra, additional, Pirenne, Jacques, additional, Schaefer, Franz, additional, Groothoff, Jaap W., additional, Levtchenko, E., additional, Haffner, D., additional, Bjerre, A., additional, Massy, Z., additional, Shtiza, D., additional, Kramar, R., additional, Oberbauer, R., additional, Baiko, S., additional, Sukalo, A., additional, van Hoeck, K., additional, Collart, F., additional, des Grottes, J.M., additional, Pokrajac, D., additional, Roussinov, D., additional, Batinić, D., additional, Lemac, M., additional, Slavicek, J., additional, Seeman, T., additional, Vondrak, K., additional, Heaf, J.G., additional, Toots, U., additional, Finne, P., additional, Grönhagen-Riska, C., additional, Couchoud, C., additional, Lasalle, M, additional, Sahpazova, E, additional, Abazi, N, additional, Ristoka Bojkovska, N, additional, von Gersdorff, G, additional, Scholz, C, additional, Tönshoff, B, additional, Krupka, K, additional, Höcker, B, additional, Pape, L, additional, Afentakis, N, additional, Kapogiannis, A, additional, Printza, N, additional, Reusz, G, additional, Berecki, Cs, additional, Szabó, A, additional, Szabó, T, additional, Györke, Z.S., additional, Kis, E., additional, Palsson, R., additional, Edvardsson, V., additional, Gianoglio, B., additional, Maringhini, S., additional, Pecoraro, C., additional, Picca, S., additional, Testa, S., additional, Vidal, E., additional, Verrina, E., additional, Jankauskiene, A., additional, Pundziene, B., additional, Said-Conti, V., additional, Gatcan, S., additional, Berbeca, O., additional, Zaikova, N., additional, Pavićević, S., additional, Leivestad, T., additional, Zurowska, A., additional, Zagozdzon, I., additional, Mota, C., additional, Almeida, M., additional, Afonso, C., additional, Mircescu, G., additional, Garneata, L., additional, Molchanova, E.A., additional, Tomilina, N.A., additional, Bikbov, B.T., additional, Kostic, M., additional, Peco-Antic, A., additional, Spasojevic-Dimitrijeva, B., additional, Milosevski-Lomic, G., additional, Paripovic, D., additional, Puric, S., additional, Kruscic, D., additional, Podracka, L., additional, Kolvek, G., additional, Buturovic-Ponikvar, J., additional, Novljan, G., additional, Battelino, N., additional, Alonso Melgar, A., additional, Schön, S., additional, Prütz, K.G., additional, Backmän, L., additional, Stendahl, M., additional, Evans, M., additional, Rippe, B., additional, Kuenhi, C.E., additional, Maurer, E., additional, Laube, G.F., additional, Tschumi, S., additional, Parvex, P., additional, Hoitsma, A., additional, Hemke, A., additional, Topaloglu, R., additional, Duzova, A., additional, Ivanov, D., additional, Pruthi, R., additional, Braddon, F., additional, Mannings, S., additional, Cassula, A., additional, and Sinha, M.D., additional

Published
2016
Full Text
View/download PDF

28. Csk homologous kinase (CHK), unlike Csk, enhances MAPK activation via Ras-mediated signaling in a Src-independent manner

Author

Cécile Bougeret, Hava Avraham, Radoslaw Zagozdzon, Wei Fu, Yigong Fu, and Rafal Kaminski

Subjects
MAPK/ERK pathway, animal structures, MAP Kinase Signaling System, Genetic Vectors, Proto-Oncogene Proteins pp60(c-src), PC12 Cells, Adenoviridae, Phosphatidylinositol 3-Kinases, Nerve Growth Factor, Animals, Phosphorylation, Cells, Cultured, Protein Kinase C, Mitogen-Activated Protein Kinase 3, Tyrosine-protein kinase CSK, biology, Chemistry, Kinase, Cell Biology, Rats, Up-Regulation, Cell biology, src-Family Kinases, Checkpoint Kinase 1, ras Proteins, biology.protein, GRB2, Signal transduction, Protein Kinases, Tyrosine kinase, Proto-oncogene tyrosine-protein kinase Src
Abstract

Substantial evidence exists supporting the notion that Csk and CHK, two negative regulatory kinases of the Src tyrosine kinase family, play distinct roles during development of the nervous system. One of the differences relies on the effects of both kinases on the MAPK transduction pathway. Specifically, CHK was shown to enhance MAPK signaling, while the role of Csk was unclear. In this work, we compared the effect of CHK versus Csk on MAPK signaling and elucidated the signaling pathway mediated by CHK leading to the activation of Erk1/2. Exogenous expression of wild-type CHK, but not Csk or a dead-kinase mutant of CHK, resulted in enhanced Erk1/2 phosphorylation in PC12 cells. CHK inhibited Src activity following stimulation of the cells with NGF. However, stimulation of Erk1/2 activation by CHK was independent of the NGF stimulation or the inhibition of Src kinase by CHK. CHK induced a complex formation between SHP-2 and Grb2, subsequently leading to the increased activity of Ras as well as Erk1/2 activation via the Raf/MEK1/2 pathway. Down-regulation of the expression of endogenous CHK by RNAi in PC12 cells led to a significant decrease in MAPK activation following NGF stimulation. Stimulation of CHK-overexpressing PC12 cells with EGF induced neurite outgrowth in the majority of cells. Taken together, this study describes for the first time the Src-independent actions of CHK and provides novel insights into CHK function in neural cells.

Published
2006

29. Requirement for CDK4 kinase function in breast cancer

Author

Qunyan Yu, Lyndsay Harris, Olle Stål, Marie Ahnström, Ewa Sicinska, Piotr Sicinski, Agnieszka Zagozdzon, Yinxin Kong, Hiroaki Kiyokawa, Humphrey Gardner, and Yan Geng

Subjects
Cancer Research, biology, business.industry, Cyclin D, Cyclin B, CELLCYCLE, Cell Biology, Cell cycle, medicine.disease_cause, medicine.disease, Cyclin D1, Breast cancer, Oncology, biology.protein, Cancer research, Medicine, Cyclin-dependent kinase 6, Kinase activity, business, Carcinogenesis, skin and connective tissue diseases
Abstract

Cyclin D1 is overexpressed in the majority of human breast cancers. We previously found that mice lacking cyclin D1 are resistant to mammary carcinomas triggered by the ErbB-2 oncogene. In this study, we investigated which function of cyclin D1 is required for ErbB-2-driven mammary oncogenesis. We report that the ability of cyclin D1 to activate cyclin-dependent kinase CDK4 underlies the critical role for cyclin D1 in breast cancer formation. We also found that the continued presence of CDK4-associated kinase activity is required to maintain breast tumorigenesis. We analyzed primary human breast cancers and found high cyclin D1 levels in a subset (approximately 25%) of ErbB-2-overexpressing tumors. We propose that this subset of breast cancer patients might benefit from inhibiting CDK4 kinase.

Published
2006
Full Text
View/download PDF

30. Mouse Development and Cell Proliferation in the Absence of D-Cyclins

Author

Qunyan Yu, Shoumo Bhattacharya, Ewa Sicinska, Katarzyna Kozar, Maria A. Ciemerych, Roderick T. Bronson, Agnieszka Zagozdzon, Hirokazu Shigematsu, Koichi Akashi, Piotr Sicinski, Yan Geng, and Vivienne I. Rebel

Subjects
Time Factors, Cyclin E, Blotting, Western, Cyclin A, Mice, Transgenic, Methylcellulose, Models, Biological, General Biochemistry, Genetics and Molecular Biology, Mice, 03 medical and health sciences, 0302 clinical medicine, Cyclin D1, Cyclin D2, Cyclins, CDC2-CDC28 Kinases, Animals, Cyclin D3, Cyclin-Dependent Kinase Inhibitor p16, 030304 developmental biology, Cyclin, 0303 health sciences, biology, Biochemistry, Genetics and Molecular Biology(all), Stem Cells, Cell Cycle, Cyclin-Dependent Kinase 2, Cyclin-dependent kinase 2, Gene Expression Regulation, Developmental, Fibroblasts, Cell cycle, Blotting, Northern, Embryo, Mammalian, Flow Cytometry, Hematopoietic Stem Cells, Cell biology, Cell Transformation, Neoplastic, Phenotype, 030220 oncology & carcinogenesis, biology.protein, Cell Division, Protein Binding
Abstract

D-type cyclins (cyclins D1, D2, and D3) are regarded as essential links between cell environment and the core cell cycle machinery. We tested the requirement for D-cyclins in mouse development and in proliferation by generating mice lacking all D-cyclins. We found that these cyclin D1(-/-)D2(-/-)D3(-/-) mice develop until mid/late gestation and die due to heart abnormalities combined with a severe anemia. Our analyses revealed that the D-cyclins are critically required for the expansion of hematopoietic stem cells. In contrast, cyclin D-deficient fibroblasts proliferate nearly normally but show increased requirement for mitogenic stimulation in cell cycle re-entry. We found that the proliferation of cyclin D1(-/-)D2(-/-)D3(-/-) cells is resistant to the inhibition by p16(INK4a), but it critically depends on CDK2. Lastly, we found that cells lacking D-cyclins display reduced susceptibility to the oncogenic transformation. Our results reveal the presence of alternative mechanisms that allow cell cycle progression in a cyclin D-independent fashion.

Published
2004

31. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice

Author

Witold Lasek, Tomasz Świtaj, Maria Marczak, Krzysztof Mucha, Radoslaw Zagozdzon, Tomasz Stoklosa, Marek Jakóbisiak, Anna Czajka, Jakub Golab, Katarzyna Kozar, Rafal Kaminski, and Adam Giermasz

Subjects
Drug, Colorectal cancer, Angiogenesis, media_common.quotation_subject, Indomethacin, Antineoplastic Agents, Stimulation, Pharmacology, General Biochemistry, Genetics and Molecular Biology, Mice, Tumor Cells, Cultured, medicine, Carcinoma, Animals, Cyclooxygenase Inhibitors, Secretion, General Pharmacology, Toxicology and Pharmaceutics, media_common, Mice, Inbred BALB C, Neovascularization, Pathologic, business.industry, Drug Synergism, Neoplasms, Experimental, General Medicine, medicine.disease, Interleukin-12, medicine.anatomical_structure, Interleukin 12, Drug Therapy, Combination, Female, business, Blood vessel
Abstract

Nonsteroidal anti-inflammatory drugs have been shown to reduce the incidence and mortality from colorectal cancer. It has recently been demonstrated that these drugs are capable of suppressing the production of pro-angiogenic factors from tumor cells. The mechanisms of antitumor action of interleukin 12 include the enforced secretion of anti-angiogenic factors and stimulation of antitumor immunity. Therefore, we hypothesized that the combination of a model nonsteroidal anti-inflammatory drug — indomethacin and interleukin 12 would result in enhanced angiogenesis-dependent antitumor effects against a colon-26 carcinoma cells transplanted into syngeneic mice. As expected the combined administration of both agents simultaneously resulted in a strengthened antitumor activity that was manifested as a retardation of tumor growth and prolongation of mouse survival. Importantly some mice were completely cured after the combined treatment. As administration of interleukin 12 and indomethacin resulted in enhanced inhibition of angiogenesis it seems possible that prevention of new blood vessel formation is one of the mechanisms responsible for the observed antitumor effects.

Published
2000

32. Formation of contacts to shallow junctions using titanium silicide with diffusion barriers

Author

Z.-H. Zhang, C.-H Lin, S.R Gooty, I Rusakova, J Li, D Marton, W Zagozdzon-Wosik, D.X Zhang, and R.J Bleiler

Subjects
Auger electron spectroscopy, Materials science, Diffusion barrier, Silicon, Spreading resistance profiling, Dopant, Mechanical Engineering, Doping, Analytical chemistry, chemistry.chemical_element, Condensed Matter Physics, chemistry.chemical_compound, chemistry, Mechanics of Materials, Rapid thermal processing, Silicide, General Materials Science
Abstract

We investigated the process integration of shallow junctions' formation and titanium silicidation. Junctions were doped with boron or arsenic during diffusion in rapid thermal processing (RTP). Dopant sources were in the form of pure layers of B or As deposited on the silicon substrate by e-beam evaporation or molecular beam epitaxy (MBE), respectively. Contact formation to the junctions was preceded by Ti deposition, either on a sacrificial layer of amorphous silicon or directly on the dopant layer. We studied the role of dopant–metal compound formation as a diffusion barrier to prevent junction degradation during the silicidation process. Such a barrier completely stops silicide formation in the case of B but is less efficient for the As doping. It also impedes boron diffusion into the silicon substrate much more than arsenic diffusion. A standard process sequence, where the junction is formed first and silicidation follows, and a modified process flow, where silicidation is done in situ together with the junction doping lead to differences in the fabricated structures. Various analytical techniques such as secondary ion mass spectroscopy (SIMS), Auger electron spectroscopy (AES), Rutherford backscattering spectroscopy (RBS), spreading resistance profiling (SRP), cross-section transmission electron microscopy (XTEM) and four-point probe were used for junction characterization.

Published
1998

33. Mortality risk in European children with end-stage renal disease on dialysis

Author

Chesnaye, Nicholas C., primary, Schaefer, Franz, additional, Groothoff, Jaap W., additional, Bonthuis, Marjolein, additional, Reusz, György, additional, Heaf, James G., additional, Lewis, Malcolm, additional, Maurer, Elisabeth, additional, Paripović, Dušan, additional, Zagozdzon, Ilona, additional, van Stralen, Karlijn J., additional, and Jager, Kitty J., additional

Published
2016
Full Text
View/download PDF

34. Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice

Author

Marek Jakóbisiak, Wojciech Feleszko, Radoslaw Zagozdzon, and Jakub Golab

Subjects
Cancer Research, Skin Neoplasms, Ratón, medicine.medical_treatment, Melanoma, Experimental, Mice, Inbred Strains, Mice, Immune system, In vivo, Antineoplastic Combined Chemotherapy Protocols, polycyclic compounds, medicine, Animals, Lovastatin, neoplasms, Cisplatin, Chemotherapy, business.industry, organic chemicals, Melanoma, nutritional and metabolic diseases, Drug Synergism, medicine.disease, In vitro, Oncology, Immunology, Cancer research, Female, lipids (amino acids, peptides, and proteins), business, Neoplasm Transplantation, medicine.drug
Abstract

Lovastatin, the drug used in the treatment of hypercholesterolaemia, has previously been reported to exert synergistic antitumour activity in a melanoma model in mice when used together with some immune response modifiers. In this study, we examined the antitumour effect of cisplatin augmented by its combined application with lovastatin, both in vitro and in vivo, in a murine melanoma model. The results of this study suggest that lovastatin may enhance the therapeutic effects of cisplatin in the treatment of malignant melanomas.

Published
1998

35. G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice

Author

Wojciech Feleszko, A. Kaca, Zygmunt Pojda, Adam Giermasz, Anna Dabrowska, Marek Jakóbisiak, A. Iwan-Osiecka, Witold Lasek, Tomasz Stoklosa, Eugeniusz K Machaj, Radoslaw Zagozdzon, and Jakub Golab

Subjects
Combination therapy, medicine.medical_treatment, Melanoma, Experimental, Antineoplastic Agents, Nitric Oxide, Leukocyte Count, Mice, Bone Marrow, Granulocyte Colony-Stimulating Factor, medicine, Animals, Drug Interactions, business.industry, Melanoma, Hematology, Immunotherapy, medicine.disease, Interleukin-12, Recombinant Proteins, Hematopoiesis, Granulocyte colony-stimulating factor, Mice, Inbred C57BL, Disease Models, Animal, Haematopoiesis, Cytokine, medicine.anatomical_structure, Oncology, Mice, Inbred DBA, Immunology, Cancer research, Myelopoiesis, Bone marrow, business, Spleen
Abstract

Summary Background IL-12 has been successfully used in experimental tumor therapy. However, administration of this cytokine induces dose-dependent suppression of hematopoiesis that could potentially limit its use in clinical trials. We decided to examine whether the myelosuppressive activity of IL-12 could be corrected by the administration of G-CSF. Materials and methods In the initial experiments the influence of IL-12 and/or G-CSF on bone marrow and spleen GM-CFC was evaluated. To examine whether G-CSF could influence the antitumor activity of IL-12 the combination therapy with these agents was carried out starting on day seven following inoculation of melanoma MmB16 cells into the foot-pads of B6D2F1 mice. To obtain insight into the mechanism of the observed augmented antitumor activity of the combination therapy with IL-12 and G-CSF, the influence of these cytokines on macrophage activity (cytotoxicity and nitric oxide release) was analyzed. Results In accord with our expectations, the application of G-CSF partially prevented the suppression of bone marrow myelopoiesis in IL-12-treated mice. Unexpectedly, G-CSF also showed potentiation of antitumor effects of IL-12 in this melanoma model. The augmented antitumor activity of combined IL-12/G-CSF immunotherapy could result from the enhanced stimulation of macrophage NO production and cytotoxicity. Conclusion The simultaneous administration of IL-12 and G-CSF partially prevented suppression of bone marrow myelopoiesis in IL-12-treated mice. Moreover, treatment with these cytokines also results in potentiated antitumor effects in a murine melanoma model.

Published
1998

37. Effect of viral infection on T-cell apoptosis in allograft recipients

Author

Rancewicz Z, J. Juskowa, M. Kasprzycka, Leszek Paczek, Andrzej Górski, Radoslaw Zagozdzon, Magdalena Durlik, and P. Wierzbicki

Subjects
Male, Human cytomegalovirus, Epstein-Barr Virus Infections, Programmed cell death, Cellular immunity, T-Lymphocytes, Apoptosis, Biology, Lymphocyte Activation, medicine.disease_cause, Virus, Postoperative Complications, medicine, Humans, Transplantation, Homologous, Transplantation, T lymphocyte, medicine.disease, Kidney Transplantation, Virology, Epstein–Barr virus, Cytomegalovirus Infections, Immunology, Drug Therapy, Combination, Female, Surgery, Viral disease, Immunosuppressive Agents, Muromonab-CD3
Published
2000

38. TCT-902 Report from the Swedish TAVI register: Comparison of two valve types

Author

Johan Nilsson, Andreas Rück, Stefan James, Dan Ioanes, Jan Harnek, Leszek Zagozdzon, Peter Holm, and Wolfgang Freter

Subjects
medicine.medical_specialty, Register (music), business.industry, Emergency medicine, medicine, Registry data, Cardiology and Cardiovascular Medicine, business
Abstract

Registry data and recent a randomized trail have established the safety and efficacy of TAVR in high risk operable and non-operable patients. Due to differences between the two common valve types procedural results and outcome may differ. The web-based on-line Swedish TAVI register have since the

Published
2012

42. 768 Peroxiredoxin-1 Protects Against Oncogene-induced Suppression of the Estrogen Receptor and is a Biomarker of Favourable Prognosis in Estrogen Receptor-positive Breast Cancer

Author

O'Leary, P.C., primary, Brennan, D.J., additional, O'Connor, D.P., additional, Hennessy, B.T., additional, Gonzalez-Angulo, A.M., additional, Mills, G.B., additional, Jirstrom, K., additional, Ponten, F., additional, Gallagher, W.M., additional, and Zagozdzon, R., additional

Published
2012
Full Text
View/download PDF

45. Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment.

Author

Jiang, Shuxian, primary, Zagozdzon, Radoslaw, additional, Jorda, Meritxell Alberich, additional, Parmar, Kalindi, additional, Fu, Yigong, additional, Williams, John S., additional, Wood, Jodi Anne T., additional, Makriyannis, Alexandros, additional, Banu, Naheed, additional, Avraham, Shalom, additional, Groopman, Jerome E., additional, and Avraham, Hava Karsenty, additional

Published
2011
Full Text
View/download PDF

46. PP212-SUN HOME ENTERAL NUTRITION IN CHILDREN – POLISH MULTICENTER SURVEY

Author

Szlagatys-Sidorkiewicz, A., primary, Popinska, K., additional, Sibilska, M., additional, Borkowska, A., additional, Toporowska-Kowalska, E., additional, Gębora-Kowalska, B., additional, Hapyn, E., additional, Kierkus, J., additional, Chlebowczyk, U., additional, Wiecek, S., additional, Daukszewicz, A., additional, Jakubczyk, M., additional, Lembas-Sznabel, M., additional, Wilczynski, M., additional, Zagozdzon, I., additional, Matras, P., additional, Zmarzly, A., additional, and Ksiazyk, J., additional

Published
2011
Full Text
View/download PDF

47. 768 Peroxiredoxin-1 Protects Against Oncogene-induced Suppression of the Estrogen Receptor and is a Biomarker of Favourable Prognosis in Estrogen Receptor-positive Breast Cancer

Author

K. Jirstrom, Radoslaw Zagozdzon, W. M. Gallagher, Fredrik Pontén, Gordon B. Mills, Bryan T. Hennessy, Darran P. O'Connor, D. J. Brennan, Patrick O’Leary, and A. M. Gonzalez-Angulo

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Oncogene, medicine.drug_class, business.industry, Estrogen receptor, respiratory system, Peroxiredoxin 1, medicine.disease, Breast cancer, Estrogen, Internal medicine, medicine, Biomarker (medicine), business, hormones, hormone substitutes, and hormone antagonists
Abstract

Peroxiredoxin-1 Protects Against Oncogene-induced Suppression of the Estrogen Receptor and is a Biomarker of Favourable Prognosis in Estrogen Receptor-positive Breast Cancer

Published
2012

48. Endocannabinoids Are Expressed in Bone Marrow Stromal Niches and Play a Role in Interactions of Hematopoietic Stem and Progenitor Cells with the Bone Marrow Microenvironment

Author

Jiang, Shuxian, primary, Zagozdzon, Radoslaw, additional, Jorda, Meritxell Alberich, additional, Parmar, Kalindi, additional, Fu, Yigong, additional, Williams, John S., additional, Wood, Jodi Anne T., additional, Makriyannis, Alexandros, additional, Banu, Naheed, additional, Avraham, Shalom, additional, Groopman, Jerome E., additional, and Avraham, Hava Karsenty, additional

Published
2010
Full Text
View/download PDF

49. PP212-SUN HOME ENTERAL NUTRITION IN CHILDREN – POLISH MULTICENTER SURVEY

Author

P. Matras, A. Daukszewicz, M. Sibilska, M. Wilczynski, Agnieszka Szlagatys-Sidorkiewicz, U. Chlebowczyk, A. Zmarzly, M. Lembas-Sznabel, Janusz Ksiazyk, Beata Gębora-Kowalska, Katarzyna Popińska, E. Toporowska-Kowalska, I. Zagozdzon, Sabina Więcek, Ewa Hapyn, Jaroslaw Kierkus, M. Jakubczyk, and Anna Borkowska

Subjects
medicine.medical_specialty, Nutrition and Dietetics, Parenteral nutrition, business.industry, Family medicine, Multicenter survey, Medicine (miscellaneous), Medicine, Critical Care and Intensive Care Medicine, business
Published
2011

50. Kinase-Independent Function of Cyclin E

Author

Geng, Yan, primary, Lee, Young-Mi, additional, Welcker, Markus, additional, Swanger, Jherek, additional, Zagozdzon, Agnieszka, additional, Winer, Joel D., additional, Roberts, James M., additional, Kaldis, Philipp, additional, Clurman, Bruce E., additional, and Sicinski, Piotr, additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results